Aborted melanoma trial ends pharma alliance

Phase 1 data highlight a manageable safety profile with IMA203 among patients with melanoma and other PRAME-positive solid tumors.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.

Support for the decision follows phase 1 findings evaluating IBI363 in patients with advanced solid tumors presented at the 2024 ESMO Plenary.